KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Other Non-Current Liabilities (2016 - 2021)

Historic Other Non-Current Liabilities for Abbott Laboratories (ABT) over the last 13 years, with Q4 2021 value amounting to $3.7 billion.

  • Abbott Laboratories' Other Non-Current Liabilities rose 2.71% to $3.7 billion in Q4 2021 from the same period last year, while for Dec 2021 it was $3.7 billion, marking a year-over-year increase of 2.71%. This contributed to the annual value of $3.7 billion for FY2021, which is 2.71% up from last year.
  • As of Q4 2021, Abbott Laboratories' Other Non-Current Liabilities stood at $3.7 billion, which was up 2.71% from $3.7 billion recorded in Q4 2020.
  • In the past 5 years, Abbott Laboratories' Other Non-Current Liabilities ranged from a high of $4.9 billion in Q4 2017 and a low of $3.7 billion during Q4 2020
  • For the 5-year period, Abbott Laboratories' Other Non-Current Liabilities averaged around $4.0 billion, with its median value being $3.9 billion (2019).
  • In the last 5 years, Abbott Laboratories' Other Non-Current Liabilities skyrocketed by 672.68% in 2017 and then plummeted by 1794.03% in 2018.
  • Abbott Laboratories' Other Non-Current Liabilities (Quarter) stood at $4.9 billion in 2017, then dropped by 17.94% to $4.0 billion in 2018, then dropped by 1.0% to $3.9 billion in 2019, then fell by 6.59% to $3.7 billion in 2020, then grew by 0.03% to $3.7 billion in 2021.
  • Its last three reported values are $3.7 billion in Q4 2021, $3.7 billion for Q4 2020, and $3.9 billion during Q4 2019.